fda tirzepatide news Grants a New Indication for Obesity Management The FDA says the Zepbound

In general, although topical treatment would be promising in melasma management, however, most of the available conventional topical formulations are challenging due to the limited skin permeability, low water solubility, low dermal bioavailability, and therefore insufficient clinical response

Gastroenterology 153 , 898900 (2017)

Lancet Diabetes Endocrinol, 5 ,

It remains, as Kucinskas outlines, preliminary data right now and there will have to be significant further tests and experiments to truly evaluate the merits and long term effects of taking this drug in conjunction with obesity-linked breast cancer, but it remains still a remarkable breakthrough that could completely change how treatment is offered in the future.

This risk is further compounded by the presence of impurities in synthetic peptides 191

& Caplan, S